Compare · NOW vs SNCE
NOW vs SNCE
Side-by-side comparison of ServiceNow Inc. (NOW) and Science 37 Holdings Inc. (SNCE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NOW and SNCE operate in Computer Software: Prepackaged Software (Technology), so they compete in similar markets.
- NOW is the larger of the two at $101.84B, about 110.6x SNCE ($921.1M).
- NOW has hit the wire 15 times in the past 4 weeks while SNCE has been quiet.
- NOW has more recent analyst coverage (25 ratings vs 5 for SNCE).
- Company
- ServiceNow Inc.
- Science 37 Holdings Inc.
- Price
- $98.77+7.39%
- $5.75+0.17%
- Market cap
- $101.84B
- $921.1M
- 1M return
- +5.34%
- -
- 1Y return
- -49.02%
- -
- Industry
- Computer Software: Prepackaged Software
- Computer Software: Prepackaged Software
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2020
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 5
ServiceNow Inc.
ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide. It operates the Now platform that offers workflow automation, artificial intelligence, machine learning, performance analytics, electronic service catalogs and portals, configuration management systems, data benchmarking, encryption, and collaboration and development tools. The company also provides information technology (IT) service management applications; IT service management product suite for enterprise's employees, customers, and partners; IT business management product suite to manage IT priorities; IT operations management product that connects a customer's physical and cloud-based IT infrastructure; IT Asset Management to automate IT asset lifecycles; and enterprise development operations product for developers' toolchain. In addition, it offers security incident management, threat enrichment intelligence, vulnerability response management, and security incident intelligence sharing security operation products; governance, risk, and compliance product to create policies and controls; human resources, legal, and workplace service delivery products; safe workplace applications; customer service management product; and field service management applications. Further, it provides App Engine product; IntegrationHub enables application to extend workflows; and professional, training, and customer support services. It serves government, financial services, healthcare, telecommunications, manufacturing, IT services, technology, oil and gas, education, and consumer products. It sells its products through direct sales team and resale partners. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. The company was incorporated in 2004 and is headquartered in Santa Clara, California.
Latest NOW
- BMO Capital Markets reiterated coverage on ServiceNow with a new price target
- SEC Form 10-Q filed by ServiceNow Inc.
- Experian accelerates AI-first experiences with ServiceNow AI Platform
- TeamViewer and ServiceNow Launch Strategic Partnership to Accelerate Autonomous IT Operations
- SEC Form S-8 filed by ServiceNow Inc.
- SEC Form S-8 filed by ServiceNow Inc.
- ServiceNow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ServiceNow Reports Second Quarter 2026 Financial Results
- ServiceNow accelerates AI-powered government reinvention across nearly all 50 U.S. states with new customer wins
- Leidos reimagines experiences for 50,000 employees and boosts operational efficiency with the ServiceNow AI Platform
Latest SNCE
- Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
- Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
- Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
- Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
- Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
- Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
- Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
- Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
- Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance